[Asia Economy Reporter Lee Seon-ae] Intronbio announced on the 28th that it has decided to terminate the contract related to the bacterial treatment 'SAL2000' with Lysovant, a subsidiary of Roivant. This decision was made by mutual agreement between the two companies. After termination, the contract deposit of 11.3 billion KRW will not be refunded.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
